Key result
Galectin-3 and TGF-β drive shared pathways of cardiac and renal fibrosis in cardiorenal syndromes.
Why the study?
There is considerable interest in understanding the cellular and tissue responses leading to cardiac and renal fibrosis in chronic cardiorenal syndromes to identify pathogenic mechanisms and therapeutic targets.
Highlights the shared pathogenic mechanisms of fibrosis in the heart and kidneys, particularly involving galectin-3 and TGF-beta, as potential therapeutic targets in cardiorenal syndromes.
Galectin-3 and TGF-β merit testing as targets in cardiorenal fibrosis; hypothesis-generating pending prospective trials.
In recent years, there has been considerable interest in cellular and tissue responses to injury that result in the deposition of extracellular matrix, collagen, elastic fibers, and the histopathological development of fibrosis. In the myocardium, fibrosis results in many recognizable clinical features, including PR interval prolongation, heart block, bundle branch block, left ventricular dyssynergy, anisotropy, atrial fibrillation, ventricular arrhythmias, systolic and diastolic dysfunction, heart failure, and cardiac death. In the kidneys, fibrosis in the glomerulus leads to glomerular sclerosis, and in the inner cortex and medulla, tubulointerstitial fibrosis leads to a reduction in renal filtration function and rapidly progressive chronic kidney disease. There are a great number of potential early mediators of cellular damage in response to events such as ischemia, neurohormonal activation, biomechanical stretch, and abnormal cell signaling. However, many studies suggest that interstitial cells in both organs, including macrophages, T lymphocytes, fibroblasts, and myofibroblasts, have common communication systems that utilize galectin-3 and transforming growth factor-β that result in the upregulation and proliferation of fibroblasts and myofibroblasts, which produce and secrete procollagen I. Procollagen I cross-links in the extracellular space to form mature collagen, which is a fundamental unit of organ fibrosis. Future research will be concentrating on the pathogenic mechanisms that turn on fibrosis and on therapeutic targets that can either prevent the activation of fibroblasts or limit their repair response to injury.
No takes yet. Share an insight, caveat, or question.
Hundae et al. (2014) conducted a review in Chronic Cardiorenal Syndromes. Cardiac and renal fibrosis in chronic cardiorenal syndromes share common pathogenic mechanisms involving galectin-3 and transforming growth factor-β.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: